Sign inJoin waitlistJoin the waitlist

AH

Arif Hussain

Co-Leader, Hormone Responsive Cancers Program · Univ of Maryland Sch of Med

Credentials: · · · ·

History

Hormone Responsive Cancers Program · Univ of Maryland Sch of Med
Present
Univ of Maryland Sch of Med
Present
University of Maryland Capital Region Health
Present

Memorial Sloan Kettering Cancer Center
1986–1987
Hematology and Medical Oncology
University of Maryland Program
1983–1986
MedStar Washington Hospital Center
1980–1983
Howard University Hospital
1976–1980
Howard University, BS, Mathematics, 1976
1972–1976

Research

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
Journal of Clinical Oncology · 2005 · 401 citations
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B
Journal of Clinical Oncology · 2001 · 282 citations
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)
Journal of Clinical Oncology · 2014 · 203 citations

HM
Heather Mannuel
12 papers
GI
Giuseppe Inesi
9 papers
NV
Nicholas Vogelzang
9 papers
JF
Joseph Fontana
8 papers
Nancy Dawson
7 papers
Rana McKay
7 papers · 4 as a resident
Young Kwok
7 papers
DR
Douglas Ross
6 papers
Pradip Amin
6 papers
Ashiq Masood
5 papers
Christos Kyriakopoulos
5 papers
Eric Small
5 papers

Grants

Multi-Faceted Targeting of Treatment-Sensitive and Treatment-Resistant Prostate Cancer
Department of Veterans Affairs · I01
Contact PI · Baltimore Va Medical Center
2009–2021
Calcium Ion Control in Cardiac Function
National Heart, Lung, and Blood Institute · P01
Project lead · $895.9K · University of Maryland Baltimore
1997–2001
Molecular Mechanism Multidrug Resistance--Mammalian Cell
National Cancer Institute · K08
Contact PI · $192.8K · University of Maryland Baltimore
1987–1990

Clinical trials

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Principal investigator · Unknown · Phase 1, Phase 2
FutureChem
2022–2025
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
Principal investigator · Completed · Phase 1
Molecular Insight Pharmaceuticals, Inc.
2009–2011